Together, our results uncovered PSPC1-CT131 as a first in its class dual inhibitor targeting oncogenic PSPC1 and PTK6/β-catenin oncogenic subcellular translocation switch and might be a promising avenue for exploring clinical interventions to prolong the survival of cancer patients. The gene discussed is PTK6; the disease is cancer.